Genmab’s Tivdak wins Japan’s approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy.
Genmab’s Tivdak wins Japan’s approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy.